Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
2 hedge funds and large institutions have $6.92M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
51% more capital invested
Capital invested by funds: $4.58M → $6.92M (+$2.35M)
38% less call options, than puts
Call options by funds: $302K | Put options by funds: $490K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $13.2K | – | – | – |
|
27
Citigroup
New York
| $5K | – | – | – |
|
|
HDIM
28
Hanson & Doremus Investment Management
Burlington,
Vermont
| $3K | – | – | – |
|
|
U
29
UBS
Zurich,
Switzerland
| $3K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
HI
31
Hudock Inc
Williamsport,
Pennsylvania
| $1K | – | – | – |
|
32
BNP Paribas Financial Markets
Paris,
France
| $480 | – | – | – |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$5K | – | – |
|
SEEL Hedge Fund Activity: Q1 2014 in Review
2 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2014, worth a combined $6.92M — up 51% from $4.58M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $2.7M. The largest seller was Tower Research Capital (TRC), cutting an estimated $5K.
- 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2014, up from 1 in Q4 2013.
- Funds reported $6.92M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2014, up 51% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2014 and 0 closed out, a net change of +1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2014 was Visium Asset Management, an estimated $2.7M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2014 was Tower Research Capital (TRC), an estimated $5K sold.
Based on aggregated 13F filings for Q1 2014.